ONCT News and Press, Oncternal Therapeutics Inc. From 11/03/22

Oncternal Therapeutics press release ( NASDAQ: ONCT ): Q3 GAAP EPS of -$0.21 (vs. -$0.19 Y/Y) beats by $0.03 . Revenue of $0.38M (-81.9% Y/Y) beats by $0.13M . For further details see: Oncternal Therapeutics GAAP EPS of -$0.21 beats by $0.03, revenue of $...

Initiated Phase 3 global registrational Study ZILO-301 of our zilovertamab product candidate targeting ROR1 in combination with ibrutinib for the treatment of patients with MCL Received acceptance for an oral presentation at the 64 th ASH Annual Meeting and Exposit...

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim clinical data from the ongoing Phase 1/2 Study CIRM-0001 will be presente...

Oncternal Therapeutics ( NASDAQ: ONCT ) is scheduled to announce Q3 earnings results on Thursday, November 3rd, after market close. The consensus EPS Estimate is -$0.23 (-21.1% Y/Y) and the consensus Revenue Estimate is $0.25M (-88.1% Y/Y). Over the last 3 months, EPS ...

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2022 financial results after the U.S. financial mark...

Clinical-stage biopharma Oncternal Therapeutics ( NASDAQ: ONCT ) on Monday said the U.S. FDA had cleared it to proceed with a phase 1/2 dose escalation study of its car T-cell therapy ONCT-808 for the treatment of aggressive B cell non-Hodgkin’s lymphoma ((B NHL)). ...

SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the receipt of a ‘Study May Proceed’ letter from the U.S. Food and Drug ...

Oncternal Therapeutics ( NASDAQ: ONCT ) said on Tuesday it had begun a Phase 3 global registrational study of zilovertamab (ZILO-301) to treat patients with relapsed/refractory mantle cell lymphoma. The Company received its first Institutional Review Board approval for...

SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the initiation of its Phase 3 global registrational study of zilovertamab, ZILO-301 (...

SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Cantor Oncology, Hematology & HemeOnc Con...